Scarica l'app Stockscreener
0.543
3.45%
0.0181
Precedente Chiudi:
$0.5249
Aprire:
$0.52
Volume 24 ore:
174.61K
Relative Volume:
0.03
Capitalizzazione di mercato:
$28.13M
Reddito:
-
Utile/perdita netta:
$-563.30K
Rapporto P/E:
-2.7204
EPS:
-0.1996
Flusso di cassa netto:
$-22.23M
1 W Prestazione:
-13.81%
1M Prestazione:
-51.52%
6M Prestazione:
-33.37%
1 anno Prestazione:
-55.85%
Intervallo 1D:
$0.52
$0.5514
Intervallo di 1 settimana:
$0.505
$0.6498
Portata 52W:
$0.38
$1.59
Promis Neurosciences Inc Stock (PMN) Company Profile
Nome
Promis Neurosciences Inc
Settore
Industria
Telefono
416-847-6898
Indirizzo
SUITE 200, 1920 YONGE STREET, TORONTO
Confronta PMN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
0.543 | 20.17M | 0 | -563.30K | -22.23M | -0.1996 |
|
VRTX
Vertex Pharmaceuticals Inc
|
398.85 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
600.13 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
463.59 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
662.29 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.92 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Promis Neurosciences Inc Borsa (PMN) Ultime notizie
ProMIS Neurosciences Reports Increased R&D Expenses and Net Loss - MSN
Promis Neurosciences chief scientific officer buys $14,595 in shares - MSN
ProMIS Neurosciences Announces $17.99M At The Market Offering to Enhance Financial Flexibility - AInvest
ProMIS Neurosciences Announces At The Market Offering - TipRanks
ProMIS Neurosciences Inc. Enters Reversal Setup in Weekly ChartsJuly 2025 Intraday Action & Risk Controlled Swing Alerts - kangso.co.kr
Candlestick Signal Suggests Reversal in ProMIS Neurosciences Inc.July 2025 Final Week & Free Fast Entry Momentum Trade Alerts - 선데이타임즈
Traders Consider Averaging Down in ProMIS Neurosciences Inc.2025 Fundamental Recap & Weekly High Conviction Trade Ideas - beatles.ru
Why ProMIS Neurosciences Inc. stock attracts strong analyst attentionJuly 2025 Pullbacks & High Win Rate Trade Tips - thegnnews.com
Market reaction to ProMIS Neurosciences Inc.’s recent newsStop Loss & Weekly Sector Rotation Insights - Newser
ProMIS Neurosciences: Promising Alzheimer's Treatment and Strong Financials Drive Buy Rating - AInvest
What makes ProMIS Neurosciences Inc. stock price move sharplyPortfolio Performance Summary & Free Long-Term Investment Growth Plans - Newser
ProMIS Neurosciences Inc. Building a Base Near Support2025 Market Sentiment & Safe Entry Momentum Tips - kangso.co.kr
Combining price and volume data for ProMIS Neurosciences Inc.July 2025 Action & Free Growth Oriented Trading Recommendations - Newser
Multi asset correlation models including ProMIS Neurosciences Inc.2025 Trade Ideas & Smart Swing Trading Techniques - Newser
ProMIS Neurosciences Reports Q2 2025 Financial Results, Receives FDA Fast Track Designation for PMN310. - AInvest
Leading vs lagging indicators on ProMIS Neurosciences Inc. performance2025 Trading Recap & Free Daily Entry Point Trade Alerts - Newser
ProMIS Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
ProMIS Neurosciences' Strategic Capital Raise and Long-Term Growth Potential - AInvest
Is ProMIS Neurosciences Inc. stock ready for a breakoutJuly 2025 Outlook & Intraday High Probability Setup Alerts - Newser
ProMIS Neurosciences: Navigating Capital-Intensive Risks for a Potential Alzheimer's Breakthrough - AInvest
ProMIS Neurosciences Reports Q2 GAAP EPS of -$0.29, Cash and Cash Equivalents at $4.5 Million - AInvest
ProMIS Neurosciences Inc. stock trend outlook and recovery pathJuly 2025 Price Swings & Weekly Hot Stock Watchlists - Newser
ProMIS Neurosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Chart overlay techniques for tracking ProMIS Neurosciences Inc.Weekly Trend Summary & High Accuracy Trade Signal Alerts - Newser
ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights - Ariva
Published on: 2025-08-13 07:52:02 - Newser
ProMIS Neurosciences Q2 2025 Financial Results & Corporate Highlights - TradingView
ProMIS Neurosciences Inc. SEC 10-Q Report - TradingView
ProMIS Neurosciences receives FDA Fast Track designation for PMN310 in Alzheimer's disease. - AInvest
ProMIS Neurosciences Announces Q2 2025 Financial Results & Corporate Highlights: FDA Grants Fast Track Designation for PMN310 in Alzheimer’s Disease, PRECISE-AD Trial Progresses on Schedule, and Secures $21.6 Million in Gross Proceeds. - AInvest
Analyzing recovery setups for ProMIS Neurosciences Inc. investorsJuly 2025 Analyst Calls & Weekly Stock Breakout Alerts - Newser
Multi factor analysis applied to ProMIS Neurosciences Inc.Dividend Hike & Daily Entry Point Trade Alerts - Newser
Institutional scanner results for ProMIS Neurosciences Inc.Free Swing Setup With Technical Confirmation - Newser
ProMIS Neurosciences PMN 2025Q2 Earnings Preview Upside Ahead on Chinese Market Expansion - AInvest
Key metrics from ProMIS Neurosciences Inc.’s quarterly dataSwing Watchlist With Tight Stop Placement - Newser
Should I buy ProMIS Neurosciences Inc. stock before earningsFree Daily Top Performing Stock Insights - Newser
ProMIS Neurosciences Inc. stock momentum explainedPortfolio Building Plan and Summary Guide - Newser
Will ProMIS Neurosciences Inc. stock recover after recent dropTrade Safety Report with Pattern Insights - Newser
ProMIS Neurosciences Inc. stock daily chart insightsEntry Opportunity Screener with Confirmation - Newser
Is ProMIS Neurosciences Inc. forming a reversal patternSector-Wise Stock Strength Trend Analysis - Newser
Can swing trading help recover from ProMIS Neurosciences Inc. lossesStock Forecast Tools for Retail Traders - Newser
Intraday pattern recognizer results for ProMIS Neurosciences Inc.Momentum Trend Signal Weekly Recap Summary - Newser
How ProMIS Neurosciences Inc. stock performs during market volatilityBuy Strategy with Smart Exit Timing - Newser
Promis Neurosciences Inc Azioni (PMN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Promis Neurosciences Inc Azioni (PMN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Shafmaster Madge K. | Director |
Sep 24 '24 |
Buy |
1.30 |
70,000 |
91,028 |
208,333 |
| Shafmaster Madge K. | Director |
Sep 23 '24 |
Buy |
1.28 |
70,000 |
89,656 |
138,333 |
| Shafmaster Madge K. | Director |
Sep 20 '24 |
Buy |
1.25 |
60,000 |
75,066 |
68,333 |
| GORDON MICHAEL S | 10% Owner |
Sep 16 '24 |
Buy |
1.22 |
76,931 |
94,071 |
76,931 |
| GORDON MICHAEL S | 10% Owner |
Sep 17 '24 |
Buy |
1.40 |
16,292 |
22,809 |
93,223 |
1.33%
0.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):